List of bibliographic references
Number of relevant bibliographic references: 11.
List of associated KwdEn.i
Nombre de documents | Descripteur |
5 | Asthma |
4 | Humans |
4 | Phenotype |
3 | Adult |
3 | Asthma (drug therapy) |
3 | Female |
3 | Male |
3 | Middle Aged |
2 | Asthma (complications) |
2 | Asthma (physiopathology) |
2 | Eosinophilia (complications) |
2 | Eosinophilia (drug therapy) |
2 | Immunology |
2 | Immunopathology |
2 | Severe asthma |
2 | Severity of Illness Index |
1 | Adrenal Cortex Hormones (administration & dosage) |
1 | Adrenal Cortex Hormones (therapeutic use) |
1 | Adrenergic beta-Agonists (therapeutic use) |
1 | Age of Onset |
1 | Age of onset |
1 | Anti-Asthmatic Agents (adverse effects) |
1 | Anti-Asthmatic Agents (pharmacokinetics) |
1 | Anti-Asthmatic Agents (therapeutic use) |
1 | Antibodies, Monoclonal (adverse effects) |
1 | Antibodies, Monoclonal (pharmacokinetics) |
1 | Antibodies, Monoclonal (therapeutic use) |
1 | Antibodies, Monoclonal, Humanized (administration & dosage) |
1 | Antibodies, Monoclonal, Humanized (adverse effects) |
1 | Arginine |
1 | Asthma (diagnosis) |
1 | Asthma (metabolism) |
1 | Asthma (pathology) |
1 | Asthma (therapy) |
1 | Biological activity |
1 | Bronchoalveolar Lavage |
1 | Classification |
1 | Clinical research |
1 | Clinical trial |
1 | Definition |
1 | Disease Progression |
1 | Dose-Response Relationship, Drug |
1 | Double-Blind Method |
1 | Drug Therapy, Combination |
1 | Eosinophilia (blood) |
1 | Eosinophilia (metabolism) |
1 | Eosinophilia (pathology) |
1 | Eosinophilia (physiopathology) |
1 | Epidemiology |
1 | Evaluation |
1 | Expansion |
1 | Glucocorticoid |
1 | Human |
1 | Immunomodulator |
1 | Injections, Subcutaneous |
1 | Intensive care |
1 | Interleukin 13 |
1 | Interleukin-13 (antagonists & inhibitors) |
1 | Interleukin-5 Receptor alpha Subunit (antagonists & inhibitors) |
1 | International |
1 | Learning |
1 | Leukocyte Count |
1 | Lung |
1 | Lung (metabolism) |
1 | Lung (parasitology) |
1 | Lung (pathology) |
1 | Medicine |
1 | Mepolizumab |
1 | Monoclonal antibody |
1 | Nasal Polyps (complications) |
1 | Nasal Polyps (drug therapy) |
1 | Nasal Polyps (metabolism) |
1 | Nasal Polyps (pathology) |
1 | Nasal Polyps (physiopathology) |
1 | Nasopharyngitis (chemically induced) |
1 | Nervous system diseases |
1 | Nutritional status |
1 | Obesity |
1 | Oral administration |
1 | Pathophysiology |
1 | Pharmacodynamics |
1 | Pharmacokinetics |
1 | Pulmonary Medicine (standards) |
1 | Quality of life |
1 | Randomization |
1 | Recommendation |
1 | Research program |
1 | Respiratory disease |
1 | Resuscitation |
1 | Severe |
1 | Sleep |
1 | Sleep disorder |
1 | Treatment |
1 | Treatment Outcome |
1 | Treatment efficiency |
1 | World |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/UK/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i -k "Sally E. Wenzel"
HfdIndexSelect -h $EXPLOR_AREA/Data/UK/Analysis/Author.i \
-Sk "Sally E. Wenzel" \
| HfdSelect -Kh $EXPLOR_AREA/Data/UK/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= UK
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Sally E. Wenzel
}}
| This area was generated with Dilib version V0.6.38. Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021 |  |